Subject: RE: REMINDER (for action by Fri 26 April COB) – EE – designating a contact for ECDC CRAb survey 2024/2025; 'save the date' for CRAb survey meetings.
From: "Liisa Lilje" <[email-masked]>
To: "Pete Kinross" <[email-masked]>
Cc: "Liidia Dotsenko" <[email-masked]>, "Anastasia.Bilozor" <[email-masked]>, "Liidia Dotsenko" <[email-masked]>, "Regina Russanova" <[email-masked]>, "TA Info" <[email-masked]>, "Natalia Kerbo" <[email-masked]>, "Andreas Hoefer" <[email-masked]>, "ARHAI Meetings" <[email-masked]>, "Dominique Monnet" <[email-masked]>, "Janne Pullat" <[email-masked]>
Date: Tue, 23 Apr 2024 10:32:09 +0300

Dear Pete Kinross,

Thank you for this kind reminder.

I’m gladly willing to be the contact person of Estonia for the upcoming ECDC 
CRAb survey.

Our OCPs will definitely be informed about the possibility to join in the 
upcoming network meetings in May and September.

Kind regards

Liisa Lilje

NFP AMR

Laboratory of Communicable Diseases

+372 5804 1264

 <mailto:[email-masked]> [email-masked]

Republic of Estonia

Health Board

+372 794 3500

[email-masked]

www.terviseamet.ee

Paldiski mnt 81, 10614 Tallinn

Estonia

This e-mail is confidential and meant for use by the person named in the 
letterhead. Any use in any way or copying of it by a person not marked as 
the addressee thereof is prohibited. If you have got this e-mail by mistake, 
please notify of it the sender without delay and delete the received e-mail 
together with all its attachments.

From: Pete Kinross <[email-masked]>
Sent: esmaspäev, 22. aprill 2024 17:25
To: Liisa Lilje <[email-masked]>
Cc: Liidia Dotsenko <[email-masked]>; Anastasia.Bilozor 
<[email-masked]>; Liidia Dotsenko 
<[email-masked]>; Regina Russanova 
<[email-masked]>; TA Info <[email-masked]>; Natalia 
Kerbo <[email-masked]>; Andreas Hoefer 
<[email-masked]>; ARHAI Meetings 
<[email-masked]>; Dominique Monnet 
<[email-masked]>
Subject: REMINDER (for action by Fri 26 April COB) – EE – designating a 
contact for ECDC CRAb survey 2024/2025; 'save the date' for CRAb survey 
meetings.
Importance: High

Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu 
saatja korral palume linke ja faile mitte avada.

ECDC NORMAL

Dear Liisa,

This is a reminder of the 27 March email below.

So far, 25 countries have designated a contact person for this upcoming ECDC 
CRAb survey.  In some countries, the NFP for AMR designated themselves. 
Therefore, until we hear from you, we will include you as the contact 
person. Please let us know if you would prefer to designate a colleague 
instead, by close of business on Friday 26 April.

After Friday, my colleagues in [email-masked] 
<mailto:[email-masked]>  will email the invitations to the 23 
May EURGen-Net virtual network meeting. For Estonia, the email will be 
addressed to you, with your OCPs for AMRISO in copy. You are all welcome to 
invite those colleagues to attend.

Participation in this online meeting does not imply an obligation for 
Estonia to participate in the CRAb survey.  Rather, at the meeting, we will 
present and discuss the survey protocol, and what it means for participating 
countries.  Here is the short version: in the ECDC CRAb survey, 
participating countries choose a 6-month survey period in Oct 2024–June 
2025.  During that survey period, laboratories/hospitals collect samples 
from hospitalised cases, and some associated metadata.

On 26 September, we will have a second online meeting to cover (basically) 
the same topics, although at that point, the survey protocol will be 
published.

If we can clarify, or if you would like to discuss any aspect, please do 
write.

Best wishes,

Pete

Pete Kinross

Principal Expert Antimicrobial Resistance and Healthcare‑Associated 
Infections

Antimicrobial Resistance and Healthcare‑Associated Infections Section 
(ARHAI)
Disease Programmes Unit (DPR), European Centre for Disease Prevention and 
Control (ECDC)

 <mailto:[email-masked]> [email-masked] /

t: +46(0)8 5860  <tel:1478> 1478

From: Pete Kinross
Sent: Wednesday, March 27, 2024 6:35 PM
To: [email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> 
; [email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]>
Cc: [email-masked] 
<mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> 
; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> 
; [email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; 'Silva Tafaj (Albania)' <[email-masked] 
<mailto:[email-masked]> >; 'Artan Bego (Albania)' <[email-masked] 
<mailto:[email-masked]> >; 'Maja Ostojic (Bosnia and Herzegovina)' 
<[email-masked] <mailto:[email-masked]> >; 'Arsim Kurti 
(Kosovo)' <[email-masked] <mailto:[email-masked]> >; 'Ana 
Kaftandzieva (North Macedonia)' <[email-masked] 
<mailto:[email-masked]> >; 'Deana Medic (Serbia)' 
<[email-masked] <mailto:[email-masked]> >; 
[email-masked] <mailto:[email-masked]> ; 'Verica 
Jovanovic (Serbia)' <[email-masked] 
<mailto:[email-masked]> >; 'Violeta Rakic (Serbia)' 
<[email-masked] <mailto:[email-masked]> >; 'Baki Can 
Metin (Türkiye)' <[email-masked] 
<mailto:[email-masked]> >; 'Zekiye Bakkaloglu (Türkiye)' 
<[email-masked] <mailto:[email-masked]> >; [email-masked] 
<mailto:[email-masked]> ; Anette M. Hammerum <[email-masked] 
<mailto:[email-masked]> >; antoni.hendrickx <[email-masked] 
<mailto:[email-masked]> >; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; Orjan.Samuelsen 
<[email-masked] <mailto:[email-masked]> >; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; Ana Rita Bastos 
Rebelo <[email-masked] <mailto:[email-masked]> >; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> 
; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked]; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; Anne-Catherine VISO 
<[email-masked] 
<mailto:[email-masked]> >; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> 
; [email-masked] <mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; Hanna Merk 
<[email-masked] <mailto:[email-masked]> >; 
[email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; [email-masked] <mailto:[email-masked]> 
; [email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; International Relations 
<[email-masked] 
<mailto:[email-masked]> >; Agne Bajoriniene 
<[email-masked] <mailto:[email-masked]> >; 
ECDC Microbiology <[email-masked] 
<mailto:[email-masked]> >; Andreas Hoefer 
<[email-masked] <mailto:[email-masked]> >; 
ARHAI Meetings <[email-masked] 
<mailto:[email-masked]> >; ARHAI <[email-masked] 
<mailto:[email-masked]> >
Subject: For action by NFPs for AMR by 19 April: please designate a national 
contact for ECDC CRAb survey 2024/2025; 'save the date' for CRAb survey 
meetings.

To: ECDC National Focal Points (NFPs) for Antimicrobial Resistance (AMR); 
NFPs for AMR Observers;

Cc: Operational Contact Points for Microbiology - Antimicrobial-resistant 
isolates (AMRISO); Contact Points for Operations (CPO) for Microbiology - 
AMRISO; Participants from Western Balkan countries and Türkiye at the ECDC 
EURGen-Net network meeting (DPR179; 29–30/11/2023); Expert Group for ECDC 
CRAb survey; National Coordinators in Coordinating Competent Bodies; 
National Correspondents.

Dear NFPs for AMR and NFP for AMR Observers,

The preparations for the ECDC CRAb survey 2024/2025 are proceeding on 
schedule (see 15 December 2023 email below) for its start on 1 October 2024.

Thank you to everyone who emailed comments on the draft ‘survey protocol’ in 
December–January. Also, many thanks to the Expert Group (see email below) 
who first met yesterday, to discuss the draft ‘laboratory manual’.  In 
April, we will email you the updated draft survey protocol and draft 
laboratory manual, for national comments.

Please can you designate a person to be a national contact for this 
EURGen-Net survey, by replying to this email by Friday 19 April?  Preferably 
avoid ‘Reply all’, if possible.  This person would be the main contact for 
survey-related emails and can be your eventual ‘National Technical 
Coordinator’ (NTC) for this study. As such, they should be nominated as an 
Operational Contact Point (OCP) for AMRISO. If they are not an OCP for 
AMRISO, we will gladly support you, during the summer months, with the 
standard nomination process ([email-masked] 
<mailto:[email-masked]> ).

Also, please can you invite up to 3 people in your country to save 2 dates 
in their calendar, for 2 virtual meetings for this ECDC CRAb survey?  Both 
meetings are designed for NTCs and Reference Laboratory staff, to prepare 
for the start of the survey.

1.	ECDC EURGen-Net CRAb survey protocol meeting
Thursday 23 May 2024, from 10:00 (at earliest) until 16:00 (at latest).
This will present the pre-final survey protocol and laboratory manual. In 
April, will email you the draft meeting agenda, asking for your designation 
of ≤ 3 people. You can designate yourself.
2.	ECDC EURGen-Net CRAb survey kick-off meeting
Thursday 26 September 2024, from 10:00 (at earliest) until 16:00 (at 
latest).
This is the kick-off meeting for the survey, covering FAQs.

If you have any additional questions or queries, please do email me.

Thank you again to all who already dedicated their time and expertise to 
this activity to prevent and control CRAb.

Best wishes,

Pete

Pete Kinross

Principal Expert Antimicrobial Resistance and Healthcare‑Associated 
Infections

AMR and Healthcare‑Associated Infections,

DPR

Phone +46 (0)8 58 60  <tel:1478> 1478

 <mailto:[email-masked]> [email-masked]

European Centre for
Disease Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone +46 (0)8 58 60 10 00

 <https://www.ecdc.europa.eu/> www.ecdc.europa.eu

Follow ECDC on:

 <http://www.facebook.com/ECDC.EU>

 <http://twitter.com/ecdc_eu>

 <http://www.linkedin.com/company/ecdc>

 <http://www.youtube.com/user/ECDCchannel>

From: Pete Kinross <[email-masked] 
<mailto:[email-masked]> >
Sent: Wednesday, 31 January 2024 17:52
To: ARHAI <[email-masked] <mailto:[email-masked]> >; ECDC 
Microbiology <[email-masked] 
<mailto:[email-masked]> >
Cc: ARHAI <[email-masked] <mailto:[email-masked]> >; ECDC 
Microbiology <[email-masked] 
<mailto:[email-masked]> >; International Relations 
<[email-masked] 
<mailto:[email-masked]> >; Andreas Hoefer 
<[email-masked] <mailto:[email-masked]> >; 
Pete Kinross <[email-masked] 
<mailto:[email-masked]> >
Subject: Invitation to register by 15 Feb 2024 for ECDC Expert Group for 
microbiological support to ECDC survey of carbapenem-resistant Acinetobacter 
baumannii (CRAb)

ECDC NORMAL

To: ECDC National Focal Points (NFPs) for Antimicrobial Resistance (AMR); 
NFPs for Microbiology; NFPs for AMR Observers; NFPs for Microbiology 
Observers; Operational Contact Points for Microbiology - 
Antimicrobial-resistant isolates (AMRISO); Contact Points for Operations 
(CPO) for Microbiology - AMRISO; EARS-Net Disease Network Coordination 
Committee Members and Observers; Participants from Western Balkan countries 
and Türkiye at the ECDC EURGen-Net network meeting (DPR179; 29–30/11/2023). 
Cc: National Coordinators in Coordinating Competent Bodies; National 
Correspondents; ECDC ARHAI, ECDC Microbiology, ECDC European and 
International Relations.

Dear colleagues,

As announced at the ECDC EURGen-Net network meeting on 29–30 November 2023, 
ECDC will establish an Expert Group for microbiological input to the ‘ECDC 
survey of carbapenem-resistant Acinetobacter baumannii (CRAb), 2024/2025’ 
(see * and the email below).

On 15 – 16 February 2024, ECDC will consult the ECDC Expert Directory to 
identify 8–15 Expert Group members. We hope that anyone interested in being 
part of the Expert Group registers with that Directory before then (URL: 
<https://www.ecdc.europa.eu/en/about-ecdc/work-ecdc/external-experts> 
https://www.ecdc.europa.eu/en/about-ecdc/work-ecdc/external-experts). Any 
expert can register. It can take 5–10 minutes. Please forward this email to 
potentially interested colleagues.

For transparency, we have specified our search terms and selection process 
below this email**. If you registered in the Directory previously, we 
recommend that you click on the hyperlink above, to verify that your 
registered skills and competencies, and CV, are up-to-date.

The scope and purpose of the Expert Group for the CRAb survey is to provide 
advice to ECDC:

A.	Support production of a laboratory manual to accompany the ECDC CRAb 
survey protocol.
This will include (A) definition of the included species for this survey of 
≤ 37 European countries; (B) specifying the best practice to prepare and 
send isolates and DNA; (C) providing options for the use/incorporation of 
nationally generated, and centrally-generated phenotypic AST data.

N.B. This will be an update of the 
<https://www.ecdc.europa.eu/en/publications-data/laboratory-manual-carbapenem-and-colistin-resistance-detection-and> 
laboratory manual for the ECDC CCRE survey, 2019. It will be shorter, as it 
does not include methods for double disk synergy assays, colistin AST and 
resistance gene specific PCRs.  The 2025 survey protocol does not include a 
request for nationally generated WGS data, as sequencing will be performed 
centrally to promote data comparability.

B.	Minor: provide input relevant to the survey protocol itself. This minor 
activity will ensure consistency with the laboratory manual.

N.B. It will not include major input to the survey design, because that will 
occur through consultation with all eligible countries, by email and during 
meetings (see the email below).

C.	Opportunity to provide input to draft analyses in 2024/2025. Those who 
meet 
<https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html> 
ICJME criteria will be included in a named author list in manuscript(s) for 
a peer-reviewed journal.

We envisage that the workload for the Group will roughly the same in 2024 
(before the survey) and in 2025/2026 (during the final stages):

*	0.5–2 days of virtual meetings (including 0.25 days during the last week 
of March 2024); and
*	2 (max 3) email consultations on draft documents.

The timeline for the preparations is shown in the email below. The first 
meeting of the Expert Group is scheduled for at 13:00–16:00 CET on 26 March 
2024.

If you have any questions about the above, please email To: 
<mailto:[email-masked]> [email-masked], with Cc: 
<mailto:[email-masked]> [email-masked].

FYI, ECDC can use the Expert Directory to identify people for a broad 
variety of activities, based on the competencies and preferences of the 
expert. For more information, please consult the Expert Directory 
<https://www.ecdc.europa.eu/en/about-ecdc/work-ecdc/external-experts> 
webpage, and particularly its Q&A section.

Best wishes,
Pete Kinross (ECDC ARHAI) and Andreas Hoefer (ECDC Microbiology)

* The primary objective of the ‘ECDC CRAb survey 2024/2025’ is to describe 
the occurrence and geographic distribution of CRAb strains, and/or 
transmissible resistance/genetic elements of critical public health 
importance within CRAb strains, among patients in acute care hospitals in 
Europe, to inform prevention and control activities. The survey period is 
October 2024–June 2025.

** The selection process will follow these steps:

1.            We will review the uploaded CVs of experts who meet the 
criteria below. The list of eligible terms competencies, professions and 
skills is purposefully broad.

2.            We will identify roughly 15 people to invite in the first 
instance (for ‘first refusal’), based on the relevance of their expertise to 
the scope of the Expert Group specified above. We will specifically seek to 
identify experts from a diverse group of countries and expert stakeholder 
groups, such as EUCAST.

3.            We will review the (obligatory) Declarations of Interest that 
are uploaded to the Directory for potential Conflicts of Interest, to ensure 
appropriate mitigation, according to the 
<https://www.ecdc.europa.eu/en/publications-data/ecdc-policy-scientific-integrity-and-independence> 
ECDC policy on scientific integrity and independence.

4.            Subsequently, if fewer than 8 people accept, we will invite 
more people, in subsequent rounds, until we have 8–15 Expert Group members.

Criteria for ECDC to identify potential members of the Expert Group for ECDC 
CRAb survey in the ECDC Expert Directory

Profession

Biologist OR Microbiologist OR Medical doctor OR Epidemiologist

Areas of competence

((Area of competence = Microbiology) AND (subcategory = ‘Antimicrobial 
susceptibility testing’ OR ‘Anti-microbial resistance’ OR ‘Clinical 
microbiology’ OR ‘Molecular testing’ OR ‘Serological testing’))

OR

((Area of competence = ‘Human medicine’) AND (subcategory = ‘All’ OR 
Infectious diseases’ OR ‘Laboratory medicine’))

Specialty

(Pathogen = ‘Acinetobacter spp.’) OR (Pathogen = ‘Gram negative bacteria’) 
OR (Disease = ‘Acinetobacter spp. infections’) OR (Disease group = ‘Diseases 
caused by antimicrobial-resistant microorganisms’)

Country

Any country (EU/EEA and non-EU/EEA countries)

Pete Kinross

Principal Expert Antimicrobial Resistance and Healthcare‑Associated 
Infections

AMR and Healthcare‑Associated Infections,

DPR

Phone +46 (0)8 58 60  <tel:1478> 1478

 <mailto:[email-masked]> [email-masked]

European Centre for
Disease Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone +46 (0)8 58 60 10 00

 <https://www.ecdc.europa.eu/> www.ecdc.europa.eu

Follow ECDC on:

 <http://www.facebook.com/ECDC.EU>

 <http://twitter.com/ecdc_eu>

 <http://www.linkedin.com/company/ecdc>

 <http://www.youtube.com/user/ECDCchannel>

From: Pete Kinross <[email-masked] 
<mailto:[email-masked]> >
Sent: Friday, December 15, 2023 7:29 PM
To: [email-masked] 
<mailto:[email-masked]> ; 
[email-masked] 
<mailto:[email-masked]> ; Boudewijn.Catry 
<[email-masked] <mailto:[email-masked]> >; 
ssabcheva <[email-masked] <mailto:[email-masked]> >; 
ivanoov <[email-masked] <mailto:[email-masked]> >; atambic 
<[email-masked] <mailto:[email-masked]> >; iva.butic <[email-masked] 
<mailto:[email-masked]> >; markella.marcou <[email-masked] 
<mailto:[email-masked]> >; lhadjihannas 
<[email-masked] <mailto:[email-masked]> >; 
helena.zemlickova <[email-masked] 
<mailto:[email-masked]> >; vladislav.jakubu 
<[email-masked] <mailto:[email-masked]> >; HENH 
<[email-masked] <mailto:[email-masked]> >; Inge.Jenny.Dahl.Knudsen 
<[email-masked] 
<mailto:[email-masked]> >; marina.ivanova 
<[email-masked] <mailto:[email-masked]> >; Liisa Lilje (EE, 
Health Board) <[email-masked] 
<mailto:[email-masked]> >; Jari Jalava <[email-masked] 
<mailto:[email-masked]> >; emmi.sarvikivi <[email-masked] 
<mailto:[email-masked]> >; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; sylvie.maugat 
<[email-masked] 
<mailto:[email-masked]> >; EckmannsT <[email-masked] 
<mailto:[email-masked]> >; Nolli <[email-masked] <mailto:[email-masked]> >; 
Michalis Polemis <[email-masked] <mailto:[email-masked]> >; 
Antonis Maragkos <[email-masked] <mailto:[email-masked]> >; 
Kassiani Mellou <[email-masked] <mailto:[email-masked]> >; 
tsiodras <[email-masked] <mailto:[email-masked]> >; Dr. Tóth Ákos 
<[email-masked] <mailto:[email-masked]> >; hajdu.agnes 
<[email-masked] <mailto:[email-masked]> >; 
[email-masked] <mailto:[email-masked]> ; Anna Margrét 
Halldórsdóttir - Landl <[email-masked] 
<mailto:[email-masked]> >; [email-masked] 
<mailto:[email-masked]> ; p.parodi <[email-masked] 
<mailto:[email-masked]> >; dancona <[email-masked] 
<mailto:[email-masked]> >; Walser-Domjan Esther <[email-masked] 
<mailto:[email-masked]> >; Rolanda Valinteliene 
<[email-masked] <mailto:[email-masked]> >; 
Monique.perrin <[email-masked] 
<mailto:[email-masked]> >; Anne Vergison 
<[email-masked] <mailto:[email-masked]> >; Borg Michael 
A at Health-MDH <[email-masked] <mailto:[email-masked]> >; 
elizabeth.a.scicluna <[email-masked] 
<mailto:[email-masked]> >; sabine.de.greeff 
<[email-masked] <mailto:[email-masked]> >; 
annelot.schoffelen <[email-masked] 
<mailto:[email-masked]> >; gunnar.skov.simonsen 
<[email-masked] <mailto:[email-masked]> >; 
ulf.dahle <[email-masked] <mailto:[email-masked]> >; Mohammed Umaer 
Naseer <[email-masked] <mailto:[email-masked]> 
 >; d.zabicka <[email-masked] <mailto:[email-masked]> >; 
[email-masked] <mailto:[email-masked]> ; Manuela Caniça 
<[email-masked] <mailto:[email-masked]> 
 >; mihaela.leustean <[email-masked] 
<mailto:[email-masked]> >; gabrielp9 <[email-masked] 
<mailto:[email-masked]> >; eva.kendrovska <[email-masked] 
<mailto:[email-masked]> >; [email-masked] 
<mailto:[email-masked]> ; milan.niks <[email-masked] 
<mailto:[email-masked]> >; helena.ribic <[email-masked] 
<mailto:[email-masked]> >; ales.korosec <[email-masked] 
<mailto:[email-masked]> >; jesus.oteo <[email-masked] 
<mailto:[email-masked]> >; baracil <[email-masked] 
<mailto:[email-masked]> >; [email-masked] 
<mailto:[email-masked]> ; petra.edquist 
<[email-masked] 
<mailto:[email-masked]> >; andreas.sandgren 
<[email-masked] 
<mailto:[email-masked]> >
Cc: hanczvikkel.adrienn <[email-masked] 
<mailto:[email-masked]> >; aiste.mierauskaite 
<[email-masked] <mailto:[email-masked]> >; 
aiste.mierauskaite <[email-masked] 
<mailto:[email-masked]> >; Dr. Tóth Ákos <[email-masked] 
<mailto:[email-masked]> >; Dr. Tóth Ákos <[email-masked] 
<mailto:[email-masked]> >; [email-masked] 
<mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; Anastasia.Bilozor 
<[email-masked] <mailto:[email-masked]> >; ama 
<[email-masked] <mailto:[email-masked]> >; Anna Margrét Halldórsdóttir - Landl 
<[email-masked] 
<mailto:[email-masked]> >; Anna Margrét 
Halldórsdóttir - Landl <[email-masked] 
<mailto:[email-masked]> >; Anna Margrét 
Halldórsdóttir - Landl <[email-masked] 
<mailto:[email-masked]> >; antoni.hendrickx 
<[email-masked] <mailto:[email-masked]> >; 
[email-masked] <mailto:[email-masked]> ; baracil 
<[email-masked] <mailto:[email-masked]> >; Brendan Denis Kinahan 
<[email-masked] <mailto:[email-masked]> >; Carina Brehony 
<[email-masked] <mailto:[email-masked]> >; daan.notermans 
<[email-masked] <mailto:[email-masked]> >; 
[email-masked] <mailto:[email-masked]> ; te-din.huang 
<[email-masked] <mailto:[email-masked]> >; dpieridou 
<[email-masked] <mailto:[email-masked]> >; d.zabicka 
<[email-masked] <mailto:[email-masked]> >; e.literacka 
<[email-masked] <mailto:[email-masked]> >; ungvari.erika 
<[email-masked] <mailto:[email-masked]> >; Walser-Domjan 
Esther <[email-masked] <mailto:[email-masked]> >; 
Walser-Domjan Esther <[email-masked] 
<mailto:[email-masked]> >; Walser-Domjan Esther 
<[email-masked] <mailto:[email-masked]> >; 
Walser-Domjan Esther <[email-masked] 
<mailto:[email-masked]> >; etienne.lucas 
<[email-masked] 
<mailto:[email-masked]> >; 
[email-masked] 
<mailto:[email-masked]> ; Errico Giulia 
<[email-masked] <mailto:[email-masked]> >; Hanna.Billstrom 
<[email-masked] 
<mailto:[email-masked]> >; HENH <[email-masked] 
<mailto:[email-masked]> >; Nolli <[email-masked] <mailto:[email-masked]> >; Ιωάννα 
Σπηλιοπούλου <[email-masked] <mailto:[email-masked]> 
 >; Isabel Cuesta De La Plaza <[email-masked] 
<mailto:[email-masked]> >; ivanoov <[email-masked] 
<mailto:[email-masked]> >; ivanstoikovbt <[email-masked] 
<mailto:[email-masked]> >; Jari Jalava <[email-masked] 
<mailto:[email-masked]> >; jaroslav.hrabak <[email-masked] 
<mailto:[email-masked]> >; [email-masked] 
<mailto:[email-masked]> ; Jelena Razmuk 
<[email-masked] <mailto:[email-masked]> >; jesus.oteo 
<[email-masked] <mailto:[email-masked]> >; j.paulo.gomes 
<[email-masked] <mailto:[email-masked]> >; 
João Vieira Martins <[email-masked] 
<mailto:[email-masked]> >; henczko.judit 
<[email-masked] <mailto:[email-masked]> >; Karl.Mertens 
<[email-masked] <mailto:[email-masked]> >; Zacharczuk 
Katarzyna <[email-masked] <mailto:[email-masked]> >; 
kati.raisanen <[email-masked] <mailto:[email-masked]> >; 
katrien.latour <[email-masked] 
<mailto:[email-masked]> >; 
[email-masked] 
<mailto:[email-masked]> ; laura.lindholm 
<[email-masked] <mailto:[email-masked]> >; laurent.dortet 
<[email-masked] <mailto:[email-masked]> >; Liisa Lilje (EE, 
Health Board) <[email-masked] 
<mailto:[email-masked]> >; loro <[email-masked] 
<mailto:[email-masked]> >; [email-masked] 
<mailto:[email-masked]> ; Manuela Caniça 
<[email-masked] <mailto:[email-masked]> 
 >; [email-masked] <mailto:[email-masked]> ; mjalbuquerque 
<[email-masked] <mailto:[email-masked]> >; 
mperezv <[email-masked] <mailto:[email-masked]> >; marianna 
<[email-masked] <mailto:[email-masked]> >; Marie.MEO 
<[email-masked] <mailto:[email-masked]> >; Marius Surleac 
<[email-masked] <mailto:[email-masked]> >; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; 
monica.monaco <[email-masked] <mailto:[email-masked]> >; 
Monique.perrin <[email-masked] 
<mailto:[email-masked]> >; niels.pfennigwerth 
<[email-masked] <mailto:[email-masked]> >; 
olivier.denis <[email-masked] 
<mailto:[email-masked]> >; Olivier Vandenberg 
<[email-masked] <mailto:[email-masked]> >; 
Orjan.Samuelsen <[email-masked] <mailto:[email-masked]> >; 
Pedro Licinio Pinto Leite <[email-masked] 
<mailto:[email-masked]> >; Apfalter Petra 
<[email-masked] <mailto:[email-masked]> >; Petra Španělová 
<[email-masked] <mailto:[email-masked]> >; Pieter-Jan 
Ceyssens <[email-masked] 
<mailto:[email-masked]> >; rainer.hartl 
<[email-masked] <mailto:[email-masked]> >; Reinis Vangravs 
<[email-masked] <mailto:[email-masked]> >; 
Sinead O'Donnell <[email-masked] 
<mailto:[email-masked]> >; solvita.selderina 
<[email-masked] <mailto:[email-masked]> >; 
ssabcheva <[email-masked] <mailto:[email-masked]> >; 
Stephan Fuchs <[email-masked] <mailto:[email-masked]> >; twolkowicz 
<[email-masked] <mailto:[email-masked]> >; semmlert 
<[email-masked] <mailto:[email-masked]> >; Urška Kramar 
<[email-masked] <mailto:[email-masked]> >; Vera Manageiro 
<[email-masked] <mailto:[email-masked]> 
 >; [email-masked] 
<mailto:[email-masked]> ; vladislav.jakubu 
<[email-masked] <mailto:[email-masked]> >; yves.dupont 
<[email-masked] <mailto:[email-masked]> >; PfeiferY 
<[email-masked] <mailto:[email-masked]> >; sigrid.kiermayr 
<[email-masked] 
<mailto:[email-masked]> >; NC_CCB_Austria 
<[email-masked] <mailto:[email-masked]> >; koen.blot 
<[email-masked] <mailto:[email-masked]> >; [email-masked] 
<mailto:[email-masked]> ; Iva Christova <[email-masked] 
<mailto:[email-masked]> >; bernard.kaic <[email-masked] 
<mailto:[email-masked]> >; kcapak <[email-masked] 
<mailto:[email-masked]> >; Elisavet Constantinou <[email-masked] 
<mailto:[email-masked]> >; Hana Orlíková <[email-masked] 
<mailto:[email-masked]> >; [email-masked] <mailto:[email-masked]> 
; Gideon Ertner <[email-masked] <mailto:[email-masked]> >; Stine Ulendorf Jacobsen 
<[email-masked] <mailto:[email-masked]> >; Kamilla Grønborg Laut <[email-masked] 
<mailto:[email-masked]> >; [email-masked] <mailto:[email-masked]> ; 
natalia.kerbo <[email-masked] 
<mailto:[email-masked]> >; Salminen Mika <[email-masked] 
<mailto:[email-masked]> >; Otto Helve <[email-masked] 
<mailto:[email-masked]> >; Anne-Catherine VISO 
<[email-masked] 
<mailto:[email-masked]> >; Paula Garcia-Lobato 
<[email-masked] 
<mailto:[email-masked]> >; Rexroth, Ute 
<[email-masked] <mailto:[email-masked]> >; [email-masked] 
<mailto:[email-masked]> ; AnderHeidenMa <[email-masked] 
<mailto:[email-masked]> >; Christakis Chatzichristodoulou 
<[email-masked] 
<mailto:[email-masked]> >; Theodora Kalomama 
<[email-masked] <mailto:[email-masked]> >; 
[email-masked] <mailto:[email-masked]> ; 
[email-masked] <mailto:[email-masked]> ; phc.office 
<[email-masked] <mailto:[email-masked]> >; Rezsőfi Judit 
<[email-masked] <mailto:[email-masked]> >; Guðrún 
Aspelund - Landl <[email-masked] <mailto:[email-masked]> >; 
Greg Martin <[email-masked] <mailto:[email-masked]> >; Kate 
Loughnane <[email-masked] <mailto:[email-masked]> >; 
patricia.garvey <[email-masked] <mailto:[email-masked]> >; 
Louise Cullen <[email-masked] <mailto:[email-masked]> >; 
Lisa.Domegan <[email-masked] <mailto:[email-masked]> >; 
kirsty.mackenzie <[email-masked] <mailto:[email-masked]> 
 >; Francesco Maraglino <[email-masked] <mailto:[email-masked]> 
 >; Antra Bormane <[email-masked]>; Dehler Silvia, Dr. med. 
<[email-masked] <mailto:[email-masked]> >; Jurgita Pakalniškienė 
<[email-masked] <mailto:[email-masked]> >; 
Jurgita Pakalniškienė <[email-masked] 
<mailto:[email-masked]> >; greta.gargasiene 
<[email-masked] <mailto:[email-masked]> >; Jean-Claude 
Schmit <[email-masked] <mailto:[email-masked]> 
 >; Gauci Charmaine at Health Regulation <[email-masked] 
<mailto:[email-masked]> >; Susan van den Hof 
<[email-masked] <mailto:[email-masked]> >; 
Hester.de.Melker <[email-masked] <mailto:[email-masked]> 
 >; Macdonald, Emily Ann <[email-masked] 
<mailto:[email-masked]> >; Poznański Dariusz 
<[email-masked] <mailto:[email-masked]> >; Zacharczuk 
Katarzyna <[email-masked] <mailto:[email-masked]> >; Mariana 
Ferreira <[email-masked] 
<mailto:[email-masked]> >; Pedro Licinio Pinto Leite 
<[email-masked] <mailto:[email-masked]> >; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; Adriana Pistol <[email-masked] 
<mailto:[email-masked]> >; jan.mikas <[email-masked] 
<mailto:[email-masked]> >; ecdc <[email-masked] <mailto:[email-masked]> >; 
Marta.vitek <[email-masked] <mailto:[email-masked]> >; 
[email-masked] <mailto:[email-masked]> ; [email-masked] 
<mailto:[email-masked]> ; Agneta Falk Filipsson 
<[email-masked] 
<mailto:[email-masked]> >; 
[email-masked]; [email-masked] 
<mailto:[email-masked]> ; Sara Bengtsson 
<[email-masked] 
<mailto:[email-masked]> >; birgitta.lesko 
<[email-masked] 
<mailto:[email-masked]> >; anette.richardson 
<[email-masked] 
<mailto:[email-masked]> >; Hanna Merk 
<[email-masked] <mailto:[email-masked]> >; Anke 
Kohlenberg <[email-masked] 
<mailto:[email-masked]> >; Daniel Palm 
<[email-masked] <mailto:[email-masked]> >; Marius 
Linkevicius <[email-masked] 
<mailto:[email-masked]> >; Andreas Hoefer 
<[email-masked] <mailto:[email-masked]> >; 
Pete Kinross <[email-masked] 
<mailto:[email-masked]> >; Dominique Monnet 
<[email-masked] <mailto:[email-masked]> 
 >
Subject: For action by NFPs for AMR by 15 Jan 2024: comments on draft ECDC 
survey protocol for carbapenem-resistant Acinetobacter baumannii (CRAb)

ECDC NORMAL

To: NFPs for AMR; Cc: OCPs for AMRISO; NCs of CCBs

Dear colleagues,

Please find attached, for review, the draft ‘ECDC survey protocol for 
genomic-based surveillance of carbapenem-resistant Acinetobacter baumannii 
at the European level. Version 1.1’ . It incorporates comments and feedback 
received during the EURGen-Net network meeting on 30 November 2023.  We 
welcome your feedback that you, or colleagues, may share to 
[email-masked] <mailto:[email-masked]> , by Monday 
15 January 2024. Preferably use comments and/or tracked changes within the 
document itself.  Also, if possible, please email one reply for your 
country.

Subsequently, the survey protocol will be processed according to the 
timetable presented at the network meeting (please see screenshot). 
Specifically, in March, we will circulate an updated draft, together with 
the request for NFPs for AMR to designate ‘national survey coordinators’ and 
‘national reference/expert laboratories’. Then, in May 2024, we will present 
a pre-final protocol at a technical meeting for these coordinators, to 
enable its publication during the summer (as ‘version 2.0’). In September, a 
final ‘kick-off meeting’ will focus on practical aspects for the survey 
(e.g. “Q&As”).

Throughout the attached draft, text in grey indicates sections that will be 
updated in parallel processes, such as Annexes 7 & 8.  I look forward to 
emailing further details in the new year.  For example, as presented at the 
network meeting (see screenshot), kindly note that a laboratory manual will 
be prepared in parallel, with an expert group, to cover 
microbiology-focussed questions. If the conclusions from that consultation 
impact the text of the survey protocol, the protocol and laboratory manual 
will be harmonised, before the May 2024 technical meeting.

Many thanks for your support to ECDC and EURGen-Net during the year, and 
best wishes for the festive season, for 2024, and beyond.

Kind regards,

Pete

Pete Kinross

Principal Expert Antimicrobial Resistance and Healthcare‑Associated 
Infections

AMR and Healthcare‑Associated Infections,

DPR

Phone +46 (0)8 58 60  <tel:1478> 1478

 <mailto:[email-masked]> [email-masked]

European Centre for
Disease Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone +46 (0)8 58 60 10 00

 <https://www.ecdc.europa.eu/> www.ecdc.europa.eu

Follow ECDC on:

 <http://www.facebook.com/ECDC.EU>

 <http://twitter.com/ecdc_eu>

 <http://www.linkedin.com/company/ecdc>

 <http://www.youtube.com/user/ECDCchannel>

Confidentiality Notice
If you are not the intended recipient of this message, you are hereby kindly 
requested, to, consecutively, refrain from disclosing its content to any 
third party, delete it and inform its sender of the erroneous transmittal.